Standard for Detecting Occult Bone Mets in Renal Cell Carcinoma May Not Be Optimal

Share this content:
Detection of occult bone metastases can be critical in determining the management of patients with renal cell carcinoma.
Detection of occult bone metastases can be critical in determining the management of patients with renal cell carcinoma.

Detection of occult bone metastases can be critical in determining the management of patients with renal cell carcinoma, especially when standard of care imaging techniques test negative.

18F-NaF PET/CT is significantly more sensitive at detecting renal cell carcinoma (RCC) skeletal metastases than conventional than bone scintigraphy or computed tomography (CT), according to an article published online ahead of print in the Annals of Oncology.

Researchers assessed the sensitivity of 18F-labelled sodium fluoride in conjunction with positron emission tomography/computed tomography (18F-NaF PET/CT) for detecting bone metastases compared to imaging with bone scinigraphy or CT.

They used an adaptive two-stage trial design, which was stopped after the first stage because of statistical efficacy.

Ten patients with stage 4 RCC and bone metastases were imaged with 18F-NaF PET/CT and 99mTc-labelled methylene diphosphonate (99mTc-MDP) bone scintigraphy, including pelvic single photon (SPECT).

RELATED: Nivolumab Superior to Everolimus for Previously-treated Renal Cell Carcinoma

A total of 77 lesions were diagnosed as malignant: 100% were identified by 18F-NaF PET/CT, 46% by CT, and 28% by bone scintigraphy/SPECT.

Standard-of-care imaging with CT and bone scintigraphy identified 65% of the metastases reported by 18F-NaF PET/CT.

Reference

  1. Gerety EL, Lawrence EM, Wason J, et al. Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial design. Annals of Oncol. 2015. [epub ahead of print]. doi: 10.1093/annonc/mdv289.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs